The U.S. FDA has advanced Eyenovia Inc.’s therapeutic program for progressive myopia treatment, MicroPine, into phase 3 clinical development.
Eyenovia develops technology that can deliver micro-therapeutics topically to the eye, according to a press release from the company. The clinical trial for MicroPine, the biopharmaceutical company’s proprietary micro-therapeutic formulation of atropine to slow the progression of myopia, is planned for the first half of 2019.
About 42% of U.S. individuals between 12 and 54 years old currently have myopia, according to the NEI. Progressive moderate to severe myopia can lead to irreversible vision loss and is associated with other significant ocular morbidities, Eyenovia said in the release.
“We look forward to working with these experts to further develop our micro-dose delivery technology, which has great potential to transform the therapeutic paradigm for front-of-the-eye diseases, Eyenovia CEO Sean Ianchulev, MD, MPH, said in the release.